Correlation Between Von Willebrand Factor, Thrombin-Antithrombin Complex, and Disease Severity in Sickle Cell Disease: Implications for Thrombosis Authors: Akaba Kingsley Onorhide, Ogar Aje Nkarense, Amon Banturaki, Ushie Godwin Published: 2026 ABSTRACT AbstractIntroductionSickle cell disease (SCD) is a hypercoagulable state characterized by elevated procoagulant factors, including Von Willebrand factor (VWF), and enhanced thrombin generation, marked by increased thrombin–antithrombin complex (TAT). Research on VWF and TAT activity during vaso-occlusive crises (VOC) remains scarce in our region.ObjectiveTo determine VWF antigen and TAT complex serum levels in SCD during steady state and VOC, and correlate these with disease severity.MethodologyThis cross-sectional study evaluated 30 SCD patients during VOC and re-evaluated the same cohort during their steady state. A control group of 30 HbAA individuals was included. Serum was analyzed for VWF and TAT complex. Analysis of Variance (ANOVA) and Pearson correlation tests were utilized (p < 0.05).ResultsMean VWF levels were highest during VOC (500.9 ± 175.6 ng/mL), followed by steady state (421.5 ± 130.9 ng/mL) and controls (395.0 ± 115.2 ng/mL) (p=0.014). TAT complex levels were highest during VOC (28.9 ± 10.4 ng/mL) compared to steady state (24.1 ± 7.8 ng/mL) and controls (4.0 ± 4.2 ng/mL) (p<0.001). Steady-state VWF positively correlated with TAT (r = 0.458, p = 0.011), while steady-state TAT positively correlated with disease severity (r = 0.401, p = 0.028).ConclusionVWF and TAT levels are significantly elevated in SCD patients, with further accentuation during VOC. These elevations strongly correlate with disease severity and specific clinical complications, establishing them as vital markers for evaluating thrombotic risk in SCD patients.Keywords: coagulation markers, disease severity, sickle cell disease Introduction Sickle cell disease (SCD) refers to a wide variety of genetically common haemoglobinopathies, with a wide variety of clinical presentations. It is the term used to describe a group of structurally genetic defects of haemoglobin (Hb). The most common form of SCD is sickle cell anaemia, which involves inheritance of sickle beta globin gene in a homozygous form (HbSS).1 Other common forms of SCD include the following: Compound heterozygosity of sickle beta globin gene; HbC (HbSC); B-thalassaemia (HbSB-thal); HbD (HbSD); HbO (HbSO); or HbLepore (HbSLepore).1 In Sub-Sahara Africa, Nigeria carries the highest disease burden, with prevalence rates of 1–3%. Prevalence rate of SCD varies in different geographical locations in Nigeria. Thus, according to the report of Inusa et al2 the prevalence rate of SCD in northern Nigeria is reported at 2.69%, while Nwogoh et al3 found a prevalence rate of 2.4% and 25% for SCA and sickle cell traits respectively in South-South Nigeria. Akaba et al4 reported the prevalence rate of 2.28% in Calabar Southern, Nigeria. SCD is a well-known state of hypercoagulability in both steady state and crisis state. Vaso-occlusion in the microcirculation is promoted by increased activation of coagulation cascade, increased platelet count, thrombin generation, depletion of natural anticoagulants, abnormal fibrinolytic system, and increase in the incidence of thrombosis.2 This hypercoagulability is reported to play a role in promoting vaso-occlusion, leading to organ damage. Thrombin generation is one of the main factors responsible for this hypercoagulable state in SCD. It is documented that increased thrombin generation results in elevation of D-dimer, thrombin-antithrombin complex (TAT), and prothrombin fragment 1.2 in steady state.3 It has been further confirmed that this hypercoagulability condition increases during sickle cell crisis.2 Thrombin plays a central role in coagulation by activating platelets and converting fibrinogen to fibrin. When thrombin binds to antithrombin, the resulting thrombin–antithrombin complex (TAT) serves as a stable marker of intravascular coagulation activation.5 Von Willebrand factor (VWF), produced by endothelial cells and megakaryocytes, mediates platelet adhesion and aggregation and also acts as a carrier for factor VIII. Increased VWF is therefore a marker of endothelial activation and may contribute to vaso-occlusive processes in SCD.6,7 Although thrombin generation assays provide a direct assessment of coagulation potential, TAT and VWF are more accessible surrogate markers in many resource-limited clinical settings. Few studies in our environment have evaluated both markers across VOC and steady state in the same SCD participants. Therefore, this study aimed to determine VWF antigen and TAT complex levels in SCD patients during VOC and steady state, compare them with HbAA controls, and examine their relationship with disease severity. Methodology Study Area The research was conducted in the Haematology Outpatient Department, Haematology/Oncology Ward, and Pathology Research Laboratory of the University of Calabar Teaching Hospital (UCTH). The UCTH is a federally owned tertiary health facility located in the Calabar municipality LGA, Cross River State. Study Design This was a cross-sectional study. Study Population The study population comprised two distinct groups: Group 1: consisted of 30 patients (aged 16–65) with SCD. To eliminate inter-individual confounding variables, the exact same cohort of 30 patients was evaluated during a documented vaso-occlusive crisis (VOC) and subsequently followed up and re-evaluated during their steady state (defined as no painful crisis, hospitalization, or blood transfusions in the preceding 1 month, or 3 months post-transfusion). Group 2: Healthy HbAA (verified by haemoglobin electrophoresis) subjects of comparable age and sex recruited from the blood donor clinic, hospital workers, and students. Sample Size Sample size is determined by the formula for a cross-sectional study n = (z2pq)/d2. Where n = minimum sample size z = Standard normal deviate (1.96) p = prevalence of SCD in Nigeria 27. q = 1-p d = degree of precision to be used. (0.05) Mathematically, the sample size (n) is = (1.96)2 x 0.02 x (1–0.02)/(0.05)2 n ≈ 30 10% attrition = 3 Thus, the sample size for this study was thirty-three (33). Thirty-three (33) in VOC group who were followed up till steady state and re-evaluated. Thirty (30) for the control group subjects. Recruitment and eligibility Inclusion criteria Patients with Sickle Cell Disease in Steady State. Patients with Sickle Cell Disease in Steady State. Patients with Sickle Cell Disease in vaso-occlusive crises. Patients with Sickle Cell Disease in vaso-occlusive crises. Exclusion Criteria The following were excluded: Patients with liver disease (deranged liver function test or proved viral hepatitis) as this might increase the level of VWF and TAT. Patients with liver disease (deranged liver function test or proved viral hepatitis) as this might increase the level of VWF and TAT. Critically ill patients with sepsis might have increased VWF and TAT level. Critically ill patients with sepsis might have increased VWF and TAT level. Pregnant women or those taking oral contraceptive as this might increase VWF. Pregnant women or those taking oral contraceptive as this might increase VWF. Patients receiving anticoagulant drugs. Patients receiving anticoagulant drugs. Acute infection and inflammation could increase VWF and TAT level. Acute infection and inflammation could increase VWF and TAT level. HIV-positive individuals. HIV-positive individuals. Controls Inclusion Criteria Apparently healthy HbAA individuals (of comparable age and sex). Blood Sampling and Storage For each subject, the venipuncture site was meticulously cleansed with methylated spirit and a total of ten milliliters (10 mL) of venous blood was drawn from the antecubital vein with minimum stasis. Two and a half milliliters (2.5 mL) of whole blood was transferred to a commercially prepared ethylene di-amine tetra-acetic acid (EDTA) bottle for basic haematological parameters, and 3.0 mL was transferred to the commercial heparin bottle for Liver Function Tests (LFTs). The sample for FBC (haematological parameters) was mixed gently to prevent cell lysis. Centrifugation of the heparinised blood sample for 10 minutes at 2000 g to get plasma for LFTs. The remaining 4.5 mL of whole blood for VWF and TAT analyses was placed into a plain sample bottle containing 0.5 mL of 0.109 M sodium citrate (3.2%) to ensure a blood: citrate ratio of 9:1. The blood was immediately centrifuged at 2000 rpm for 15 min. Plasma obtained was centrifuged again at 4000 rpm for 15 min. Platelet-poor citrated plasma stored at −80°C for future analyses. (Platelet-poor plasma has less than 10,000 platelets/mL). Test Procedures Basic Haematological Parameters: The full blood count which consists of haematocrit, haemoglobin concentration, and total white cell and platelets count was done from the EDTA sample using automated blood cell counter (Sysmex Haematology Autoanalyser KN21 model). Principles of the technique involved in the procedure are electrical impedance and light scattering. This was carried out in the haematology laboratory, UCTH. Severity Score It is based on combination of clinical and laboratory parameters such as anaemia, complications, crisis and transfusion score leading to the disease severity score. Anaemia score Hb ≥ 10 g/dl → 0 Hb ≥ 10 g/dl → 0 Hb ≥ 8 < 10 g/dl → 1 Hb ≥ 8 < 10 g/dl → 1 Hb ≥ 6 < 8 g/dl → 2 Hb ≥ 6 < 8 g/dl → 2 Hb ≥ 4 < 6 g/dl → 3 Hb ≥ 4 < 6 g/dl → 3 Hb < 4 g/dl → 4 Hb < 4 g/dl → 4 Complication Score A Score of 1 Was Given for Each Complication Presence of any of these complications was given a score of “Yes”{1} and “No”{0}; Pneumonia: Yes/No; Osteomyelitis: Yes/No; ACS: Yes/No; Heart Failure: Yes/No; Avascular necrosis of the femoral head: Yes/No; Renal Failure: Yes/No; Pigment gallstone and Jaundice: Yes/No; Liver Failure: Yes/No; Seizure: Yes/No; Growth Retardation: Yes/No; Dehydrated: Yes/No; Acute Splenic Sequestration: Yes/No; VOC/Pain: Generalized (2), Localized (1), No (0). Transfusion Score Past blood transfusion score – Yes; Number of times per year; 1–2[1]; ≥ 3[2] Crisis score Number of crisis per year; 0–1[0]; 2–3[1]; ≥4[2] Disease severity scores; Mild - (≤3); Moderate - (>3 ≤ 7); Severe - (>7). Data Analysis Data were analyzed using SPSS version 26. The Shapiro–Wilk test was used to assess normality. Normally distributed continuous variables were summarized as mean ± standard deviation and compared across the three study conditions using one-way analysis of variance (ANOVA), with Bonferroni post-hoc testing for pairwise comparisons. Where variables were not normally distributed, non-parametric tests were planned. Categorical variables were summarized as frequencies and percentages. Pearson correlation analysis was used for normally distributed variables, while Spearman correlation was considered for non-normal variables. Statistical significance was set at p < 0.05. Data are presented in tables and figures. Ethical Issues Approval was gotten from the Ethical Committee of University of Calabar Teaching Hospital with NHREC reference number 07/10/2012 and HREC reference protocol number UCTH/HREC/33/Vol.III/060. This study was conducted in full compliance with the Declaration of Helsinki. All patient data remained confidential. Results A total of 63 subjects, including 33 sickle cell disease (SCD) subjects and 30 controls, were recruited for the study. However, three patients with SCD were lost to follow-up, and only 30 of them completed the study. Sociodemographic Parameters The SCD group contained 26 subjects (86.7%) with the genotype HbSS, while there were 4 subjects (13.3%) with the genotype HbSC. The mean age for the SCD subjects was 22.7 ± 3.3 years (95% CI: 21.5–23.9), and the age for the control group was 25.1 ± 6.3 years (95% CI: 22.7–27.4). This difference in the means was not statistically significant (t = −1.828, p = 0.073). The majority of enrolled SCD subjects belonged to the age group 18–21 years (Table 1). The proportion of male and female SCD subjects in the experiment was 11 (36.7%) and 19 (63.3%), respectively. In contrast, among the control population, there were 19 men (63.3%) and 11 women (36.7%). The difference between the two groups in terms of their gender distribution was statistically insignificant (p = 0.071). Table 1Demographic Characteristics of the Study PopulationSCDn = 30Controlsn = 30χ2P valueAge group (years) 18–2115 (50.0)10 (33.3) 22–259 (30.0)9 (30.0)2.9460.400 26–296 (20.0)7 (23.3) >290 (0.0)4 (13.3)Sex Male11 (36.7)19 (63.3)3.2700.071 Female19 (63.3)11 (36.7)Education Secondary10 (33.3) Tertiary20 (66.7)HB Phenotype SS26 (86.7) SC4 (13.3) Demographic Characteristics of the Study Population Clinical Characteristics and Disease Severity Score of the SCD Subjects Table 2 shows the clinical characteristics of the patients with SCD. One-third of them had a steady-state haemoglobin level between 8–9.9g/dL, while in two-thirds, the steady-state haemoglobin level was between 6 and 7.9g/dL. Table 2Clinical Characteristics and Disease Severity Score of SCD SubjectsSteady State Hb (g/dl) ≥101 (3.3) 8–9.910 (33.3) 6–7.918 (60.0) 4–5.91 (3.3)Organ complications Retinopathy6 (20.0) AVN5 (16.7) SCLU2 (6.7) IHD2 (6.7) Nephropathy2 (6.7) Priapism3 (27.2) *Blood transfusion18 (60.0)Hospital admissions ≥3 per yr.5 (16.7)Frequency of VOC 0–19 (30.0) 2–312 (40.0) ≥49 (30.0)Severity score 11 (3.3) 21 (3.3) 312 (40.0) 46 (20.0) 58 (26.7) 62 (6.7)Disease severity category Mild14 (46.7) Moderate16 (53.3)Note: *Percentage expressed as the proportion of males only.Abbreviations: AVN, vascular necrosis; SCLU, sickle cell leg ulcer; IHD, ischaemic heart disease; VOC, vaso-occlusive crisis. Clinical Characteristics and Disease Severity Score of SCD Subjects Note: *Percentage expressed as the proportion of males only. Abbreviations: AVN, vascular necrosis; SCLU, sickle cell leg ulcer; IHD, ischaemic heart disease; VOC, vaso-occlusive crisis. The most frequent organ complication was retinopathy (n = 6, 20.0%) followed by avascular necrosis of the femur (n = 5, 16.7%). Other complications included chronic leg ulcers, ischaemic heart disease, and nephropathy, with a frequency of 2 (6.7%). Three males (27.2%) had priapism. Eighteen (60.0%) SCD subjects had been transfused. Twelve (40.0%) participants reported the frequency of VOC per year to be 1–2 episodes on average. Nine patients reported 0–1 episode and ≥4 episodes per year. Five (16.7%) patients reported three or more hospital admissions. The disease severity scores of SCD subjects ranged from 1 to 6, as shown in Table 2. Twelve participants (40.0%) had a score of 3. Fourteen (46.7%) subjects had mild disease, while 16 (53.3%) had moderate disease. Haematological Parameters of the Study Population Table 3 indicates the distribution of the haematological parameters for SCD patients and control groups. The mean packed cell volume among SCD patients was lower than that of controls (22.3 ± 3.3% vs 39.3 ± 3.0%; p < 0.001). Mean haemoglobin concentration was also lower among SCD patients than controls (7.2 ± 1.2 g/dL vs 12.7 ± 1.0 g/dL; p < 0.001). Mean white blood cell count was higher among SCD patients than controls (14.7 ± 4.6 × 109/L vs 7.3 ± 1.9 × 109/L; p < 0.001). Platelet counts were also higher among SCD patients than controls (370.8 ± 82.3 × 109/L vs 310.8 ± 73.1 × 109/L; p = 0.004). Table 3Haematological Parameters of the Study PopulationSCDn = 30Controlsn = 30T testP valueMean ± SD95% CIMean ± SD95% CIPCV (%)22.3 ± 3.321.1–23.639.3 ± 3.038.2–40.5−20.7540.000Hb (g/dL)7.2 ± 1.26.7–7.612.7 ± 1.012.4–13.1−19.4020.000WBC x109/L14.7 ± 4.613.0–16.57.3 ± 1.96.6–8.08.0960.000ANC x109/L9.7 ± 4.28.2–11.34.7± 1.54.1–5.26.3160.000AL x109/L4.0 ± 1.73.3–4.61.9 ± 0.61.7–2.26.0880.000MCV fL90.5 ± 7.787.7–93.484.8 ± 6.882.2–87.33.0910.003MCHC g/dL32.1 ± 1.631.5–32.732.5 ± 0.432.3–32.6−1.0260.309MCH ρg30.0 ± 3.128.8–31.128.4 ± 0.928.0–28.72.6320.011Platelet count370.8 ± 82.3340.0–401.5310.8 ± 73.1283.5–338.12.9860.004Abbreviations: PCV, packed cell volume; Hb, Haemoglobin; WBC, White Blood Cell Count; ANC, Absolute Neutrophil Count; ALC, Absolute Lymphocyte Count; MCV, Mean Corpuscular Volume; MCHC, Mean Corpuscular Haemoglobin Concentration. Haematological Parameters of the Study Population Abbreviations: PCV, packed cell volume; Hb, Haemoglobin; WBC, White Blood Cell Count; ANC, Absolute Neutrophil Count; ALC, Absolute Lymphocyte Count; MCV, Mean Corpuscular Volume; MCHC, Mean Corpuscular Haemoglobin Concentration. Von Willebrand Factor Table 4 illustrates the concentrations of VWF and thrombin-antithrombin in the study population. The mean VWF was highest during the SCD crisis (500.9±175.6ng/mL) compared to the steady state (421.5±130.9ng/mL) and the control group (395.0±115.2ng/mL). There were statistically significant differences among the mean values between the groups (p=0.014). Further comparisons between each pair of groups indicated that VWF during the SCD crisis state had higher values compared to that in the steady state, but there was no statistically significant difference (p=0.052). VWF concentrations during the SCD crisis were significantly higher when compared to those in the control group (0.008). The mean difference between VWF during the steady state and the control group was statistically insignificant (p=0.409). Table 4The Distribution of VWF and Thrombin-Antithrombin Levels in the Study PopulationSCD CrisisSCD Steady StateControlF valueP valueMean ±SD95% CIMean ±SD95% CIMean ±SD95% CIVWF (ng/mL)500.9 ± 175.6435.4–566.5421.5 ± 130.9372.6–470.4395.0 ± 115.2352.0 ± 438.04.4670.014TAT (ng/mL)28.9 ± 10.425.0–32.824.1 ± 7.821.2–27.14.0 ± 4.22.4–5.584.6430.000Abbreviations: 95% CI, 95% confidence interval; SD, Standard deviation; VWF, von Willebrand factor; TAT, Thrombin-antithrombin complex. The Distribution of VWF and Thrombin-Antithrombin Levels in the Study Population Abbreviations: 95% CI, 95% confidence interval; SD, Standard deviation; VWF, von Willebrand factor; TAT, Thrombin-antithrombin complex. These findings are summarized in Table 4 and illustrated in Figure 1. Boxplot showing the distribution of VWF in the study population. The boxplot summarizes the spread of VWF values among participants with sickle cell disease, showing the median, interquartile range, overall variability, and any extreme values. Higher VWF levels may reflect endothelial activation and a prothrombotic state relevant to disease severity and thrombosis risk. Figure 2 further illustrates the combined distribution of VWF and TAT after the VWF distribution shown in Figure 1. As shown in Table 5, steady-state VWF was positively correlated with TAT (r = 0.458, p = 0.011). However, neither VWF nor TAT demonstrated significant correlations with most haematological parameters in steady-state SCD subjects. Distribution of von Willebrand factor (VWF) and thrombin–antithrombin complex (TAT) levels in the study population. The boxplot compares the variability of VWF and TAT concentrations among participants with sickle cell disease. VWF represents endothelial activation and platelet adhesion potential, while TAT reflects thrombin generation and coagulation activation. Together, these markers illustrate the relationship between coagulation activity and disease severity, with potential implications for thrombosis risk. Table 5Correlation Between Haematological Parameters in Steady State VWF, and TATVWFTATHbWBCANCALCPLTVWFr10.4580.127−0.021−0.030−0.0380.155p0.0110.5050.9110.8760.8440.412TATr0.45810.242−0.188−0.3080.2070.049p0.0110.1970.3200.0980.2730.799Hbr0.1270.2421−0.219−0.3430.240−0.067p0.5050.1970.2440.0640.2020.726WBCr−0.021−0.1880.04910.884−0.409−0.068p0.9110.3200.7990.0000.0250.722Neutr−0.004−0.436−0.3970.3731−0.051−0.078p0.9850.0160.0300.0420.7890.681Lymphr−0.0460.4470.453−0.397−0.10410.049p0.8090.0130.0120.0300.5830.796PLTr0.1550.049−0.067−0.068−0.0510.0401p0.4120.7990.7260.7220.7890.836Abbreviations: PCV, Packed cell volume; Hb, haemoglobin; WBC, white blood cell count; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; PLT, platelet count; VWF, von Willebrand factor; TAT, thrombin-antithrombin complex; r, Pearson correlation coefficient; p/P value, probability value. Correlation Between Haematological Parameters in Steady State VWF, and TAT Abbreviations: PCV, Packed cell volume; Hb, haemoglobin; WBC, white blood cell count; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; PLT, platelet count; VWF, von Willebrand factor; TAT, thrombin-antithrombin complex; r, Pearson correlation coefficient; p/P value, probability value. Correlation Between SCD Steady State VWF, TAT and Disease Severity Scores The correlation between steady-state VWF, TAT, and disease severity score is summarized in the Results text. VWF correlated positively with TAT (r = 0.458, p = 0.011), while TAT correlated positively with disease severity (r = 0.401, p = 0.028). VWF did not correlate significantly with disease severity (r = 0.023, p = 0.903). Correlation of the Clinical Characteristics of the SCD Subjects with VWF and TAT Levels Table 6 shows the correlation between clinical characteristics and VWF and TAT. There was no significant correlation between VWF levels and the clinical characteristics of SCD subjects in the steady state. A positive correlation was observed between TAT and retinopathy (r = 0.380, p = 0.038) and avascular necrosis (r = 0.465, p = 0.010). Table 6Correlation of the Clinical Characteristics of the SCD Subjects with VWF and TAT LevelsVWFTATrP valuerP valueFrequency of VOC−0.0460.8110.0880.642Hospital admission−0.2280.2260.0510.789Blood transfusion−0.0240.902−0.0350.853Retinopathy0.0290.8800.3800.038AVN0.1810.3390.4650.010SCLU−0.0150.935−0.0930.626IHD−0.0770.685−0.2160.251Nephropathy0.1240.516−0.0080.968Priapism0.0700.711−0.1540.417 Correlation of the Clinical Characteristics of the SCD Subjects with VWF and TAT Levels Correlation Between VWF and TAT in SCD Crisis State During the SCD crisis period, there was no significant correlation between VWF and TAT (r = 0.146, p = 0.441). Because this finding is adequately described in the text, the previous standalone correlation table was removed to reduce table density. Discussion SCD is a hypercoagulable disorder, and the role of prothrombotic proteins in SCD disease pathogenesis has been extensively studied. Some studies suggest that sustained activation of the coagulation system is a hallmark feature of the disease, and hypercoagulability is not only a secondary phenomenon but also plays a direct role in the pathophysiology of SCD, including vaso-occlusive crisis.1,8 Limited studies exist on the role of von Willebrand factor (VWF) and thrombin antithrombin complex (TAT) in the pathogenesis of vaso-occlusive crises in our environment. Thus, the index study aimed to determine the changes in the levels of VWF and TAT and their role in the pathogenesis of the vaso-occlusive crises. The study population included mostly young adults aged 18–21 years with higher education and mostly females. This is because the study was conducted among academics where the number of study participants consisted of mostly undergraduates. Subjects included those with moderate disease severity since none of the subjects were severely ill. This may have been attributed to improved health-seeking behavior of the subjects facilitated by friendly day care service offered by the sickle cell day clinic at the hospital. Furthermore, the presence of the social network offered by the sickle cell club consisting of medical professionals made it easy for the patients to attend health facilities. There was a marked elevation of von Willebrand factor levels in the subjects with SCD in the state of VOC compared to control subjects. The difference in mean VWF levels of SCD subjects in VOC and steady states was markedly elevated, but it was not statistically significant. There was no marked difference in the mean VWF levels of SCD subjects in steady state and control subjects. A study on the comparison of mean VWF levels in SCD subjects in VOC and steady states was conducted by Akaba et al, in the same institution. In contrary to the current study, this study revealed significant differences in the levels of VWF levels in SCD subjects. This may have been attributed to the relatively small sample size. Whereas 60 SCD subjects participated in the study conducted by Akaba et al, only 30 SCD subjects were used in the current index study.2,3 Likewise, other studies conducted by Schnog et al, Sins et al, and Al-Awadhi et al also revealed significantly elevated VWF levels in subjects with SCD in the states of VOC.9–11 An animal study conducted by Lizarralde-Iragorri and Shet revealed that activation and secretion of von Willebrand factor by endothelium is due to widespread activation caused by plasma free haeme that causes abnormal tissue factor and P-selectin expression and VWF synthesis and release.12 While our data demonstrates a clear elevation of VWF during VOC compared to steady states, the cross-sectional, observational nature of our study limits the ability to determine strict causality. It remains clinically debated whether the acute elevation of VWF is a primary driver that generates the microvascular occlusion, or if it is a secondary acute-phase reactant released subsequent to the endothelial damage caused by the sickling event itself. It is highly likely that a cyclical, bidirectional relationship exists where endothelial injury triggers VWF release, which subsequently propagates further platelet adhesion and vaso-occlusion. Significantly high TAT levels were seen in SCD subjects compared to the control group. Furthermore, it has been observed that the TAT levels in SCD subjects during VOC crisis were significantly higher than those during the steady state period. This could imply that thrombin activation might occur widely in SCD subjects with even more accentuation during vaso-occlusive crisis. However, there has been only a handful of literature on TAT in sickle cell disorders (SCD); hence, it was necessary to conduct this study to add information on the subject. According to recent literature by Noubouossie13 and Key and Ataga,14 a marked increase has been reported in various markers of thrombin and fibrin generation in SCD steady state than Hb AA controls, including TAT, fibrinopeptides A, d-dimers, prothrombin fragments, and plasmin-antiplasmin complexes. These findings have been supported by this study. However, according to these authors’ review article, there is inconsistent evidence showing further increase in these markers of thrombin and fibrin generation in association with VOC. Yee et al15 found that Hb SS patients had a hypercoagulable thromboelastography (TEG) profile, characterized by a shorter reaction time, angle, maximum amplitude and increased coagulation index, compared to age- and race-matched healthy controls. They also found that patients with Hb SS in acute painful crises exhibited increased maximum amplitude and coagulation index compared to Hb SS subjects with baseline condition, albeit with limitations in the small number of patients included in acute pain crises. In a study by Shah et al16 using the commercial thrombin generation test (CAT) method, it has been found that there are significant differences in all phases of thrombin generation in VOC compared to steady state, which is similar to the observation of significant increases in the TAT levels observed in this study. In another relevant study conducted by Setty et al,17 it has been found that markers of thrombin generation, including TAT, are significantly elevated in patients with SCD including HbSS (n=25) and HbSC (n=15). In another study by Soliman and Ragab18 comparing VWF antigen levels among 24 steady state SCD patients, 24 SCD patients during painful crisis and 20 healthy age- and sex-matched controls, TAT levels were significantly elevated in SCD steady state compared to control subjects and a further increase during painful crisis. Significant increases in TAT levels have also been found in SCD adolescent subjects compared with age-and sex-matched adolescent subjects with β-thalassaemia and control groups.19 These findings are consistent with those observed in this study. A significant positive correlation was observed between VWF and TAT in steady state SCD subjects. High VWF secretion is associated with activation of the coagulation cascade, leading to an increase in thrombin generation. Therefore, a positive correlation was established between VWF and TAT levels in the study subjects. These findings are associated with a hypercoagulable state characteristic of SCD. It should be noted that the relationship between VWF and TAT remains largely unknown; therefore, the literature on the subject is scarce. This index study can help fill this void in the literature and can be used as a reference in future studies. There was no significant relationship between VWF, TAT, and other haematological indices in this study. This finding is congruent with previous findings by Akaba et al in their study carried out in Calabar.20 Similar results were obtained by Setty et al17 when they assessed correlations between TAT, erythrocyte positive phosphatidylserine (PS) erythrocytes, and platelets, among other indicators of increased thrombin generation (such as prothrombin fragments), in SCD patients. In this particular study, they found no significant correlations between TAT and positive PS erythrocytes and platelets, but they found a significant positive correlation between prothrombin fragment and positive PS erythrocytes. These results indicate that there is a limited role of platelets in increased thrombin generation in SCD, but this needs to be explored further in future studies. Similarly, in another study, Ataga et al21 evaluated the correlation between TAT as a marker of coagulation activation with various haematological indices in 67 adult patients with SCD in steady state. In this study, there was no significant correlation between TAT and haematocrit, total white blood cells, neutrophils, lymphocytes, and platelets. The relationship between TAT and haematological indices has been evaluated in other clinical conditions. In their study on preeclampsia-eclampsia patients, Okuonghae et al22 evaluated the relationship between TAT levels and haematological indices and observed no significant correlation except between platelets and TAT. The latter showed a significant negative correlation. Preeclampsia-eclampsia condition is different from SCD in that it is associated with platelet depletion due to associated HELLP and DIC syndromes. Positive correlations were found between TAT in the steady state and disease severity in the case of SCD. Only a few studies have investigated the correlation between TAT and disease severity scores, but some studies have evaluated the correlation between TAT and individual component factors that constitute disease severity score. When the clinical characteristic of the SCD patients in relation to complications were correlated with VWF and TAT levels, significant positive correlations were noted between TAT and retinopathy and between TAT and AVN in steady state. On the other hand, Ataga et al21 did not observe any significant relationship between TAT level and stroke, AVN, leg ulcers, occurrence of three or more VOC crises in the preceding year, acute chest syndrome, and priapism but found a significant correlation between retinopathy and elevated TAT. In this particular study, we observed a positive correlation between TAT and AVN. The difference in results in this respect could be attributed, in part, to differences in sample size and subjects’ complication numbers in the two studies. Some of the strengths of this study include the following. Evaluation of the same subjects in both steady state and VOC state is a major strength in this study since it eliminated biases/confounders associated with recruitment of SCD patients with different phenotypes into both conditions. Hence, one can conclude that either the presence or absence of a VOC crisis is the cause of differences observed. Very limited literature on thrombin generation in relation to SCD patients exists, particularly in Nigeria; hence, this study provides a point of reference in such studies. This study is also unique in that very few studies evaluating thrombin generation potential in relation to disease severity in SCD have been performed. This study has limitations. First, clinical characteristics were partly based on verbal reports and may therefore be affected by recall bias. Second, the sample size was modest and included both HbSS and HbSC phenotypes, which may limit generalisability. Third, although TAT is a recognized marker of intravascular coagulation activation, we did not directly perform a thrombin generation assay. Recent evidence suggests that TGA parameters may provide additional information about hypercoagulability and VOC risk in SCD. Future studies should therefore include larger phenotype-specific cohorts and direct thrombin generation testing alongside VWF, TAT, and endothelial activation markers. Conclusion From this study, VWF and TAT complex levels are significantly elevated in patients with sickle cell disease compared to healthy controls, with a marked further increase observed during vaso-occlusive crises. In the steady state, TAT levels demonstrate a strong positive correlation with VWF levels, overall disease severity scores, retinopathy, and avascular necrosis. These findings highlight the utility of VWF and TAT as accessible markers of hypercoagulability and disease severity in SCD patients. Funding Statement The study was funded by the authors. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure No conflicts of interest declared. References